AstraZeneca’s Symbicort for asthma available for 6-12 y.o. children in USA, FDA issues exclusivity rights
AstraZeneca’s Symbicort Inhalation Aerosol is going to be available for 6-12 years old children with asthma in the US
Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca’s Symbicort Inhalation Aerosol is going to be available for 6-12 years old children with asthma in the US
Here’s a lightly edited version of the interview with Dr. Joseph Gulfo, the executive director of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University, the author of “Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances” and the former President and CEO of the medical device firm MELA Sciences:
U.S. Food and Drug Administration (FDA) has approved Allergan’s Rhofade skin desease cream, a topical treatment of persistent facial erythema (redness)…
The Food and Drug Administration is warning consumers not to purchase or use PNC-27, a product promoted and sold through http://PNC27.com,…
The U.S. Food and Drug Administration (FDA) has noticed that lately for certain reason, there are fewer number of people willing to participate in clinical trials for different medications. Therefore, it has decided to encourage patients to take a part in helping researching companies to develop new drugs.
The U.S. Food and Drug Administration (FDA) has said that it plans to take a better look on how drug-makers describe their products and to make them focus on better explaining what the drug exactly do, and how consumers and healthcare professionals (HCPs) can detect false promotions.
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
Allergan has won FDA’s approval to sell its breast implants in US.
Mylan has had a rather busy week, as it got approvals for three of its generic medicines in last three days. It announced launching three generics into the multi-billion U.S. worth market on Wednesday and Thursday.
Seattle Genetics Inc said four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage studies.